Aurinia Pharmaceuticals (AUP) opened at 8.27 on Friday. The company has a 50-day moving average of $7.82 and a 200 day moving average of $8.59. Aurinia Pharmaceuticals has a one year low of $2.75 and a one year high of $14.17. The firm’s market capitalization is $690.42 million.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with our FREE daily email newsletter.